Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 shows late clinical disease relevance led by migraine disorder. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O60894. Start with migraine disorder, then reuse UniProt O60894 as the stable protein anchor across project notes and exports.
Start with migraine disorder, then reuse UniProt O60894 as the stable protein anchor across project notes and exports.
Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 shows late clinical disease relevance led by migraine disorder. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with migraine disorder because it currently carries late clinical support. Linked drugs include ZAVEGEPANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyReceptor activity-modifying protein 1
Review this target as Calcitonin-gene-related peptide receptor, CALCRL/RAMP1, mapped to UniProt O60894. ChEMBL maps the protein component as Receptor activity-modifying protein 1. Sequence length is 148 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 as ChEMBL target CHEMBL2107838, mapped to UniProt O60894. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 is the right protein anchor across sources, using UniProt O60894 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why migraine disorder is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | O60894 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Receptor activity-modifying protein 1 |
| UniProt Accession | O60894 |
| Component Type | Protein |
| Sequence Length | 148 aa |
Receptor activity-modifying protein 1
Review this target as Calcitonin-gene-related peptide receptor, CALCRL/RAMP1, mapped to UniProt O60894. ChEMBL maps the protein component as Receptor activity-modifying protein 1. Sequence length is 148 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 shows late clinical disease relevance led by migraine disorder. 2 more disease programs remain visible in the same review block.
Start review with migraine disorder because it currently carries late clinical support. Linked drugs include ZAVEGEPANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4643006 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL3893283 | 10.96 | Ki | 0.011 | Preclinical |
| CHEMBL2035984 | 10.85 | Ki | 0.014 | Preclinical |
| CHEMBL3981883 | 10.82 | Ki | 0.015 | Preclinical |
| CHEMBL3991065 | 10.82 | Ki | 0.015 | Approved |
| CHEMBL2035985 | 10.8 | Ki | 0.016 | Preclinical |
| CHEMBL3914484 | 10.77 | Ki | 0.017 | Preclinical |
| CHEMBL4638112 | 10.7 | Ki | 0.01995 | Preclinical |
| CHEMBL2371890 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL264010 | 10.7 | Ki | 0.02 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 15 | 20 | 8.8 |
| cell-based format | 10 | 84 | 9.5 |
| cell membrane format | 2 | 16 | 6.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 6 | 30 | 6.8 |
| protein complex format | 1 | 2 | 10.7 |